- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07537413
Ceftriaxon-Dosierung für nicht-kritische ambulant erworbene Pneumonie (DC-CAP)
Pragmatische randomisierte Studie zur Bewertung der Dosierung von Ceftriaxon bei ambulant erworbener Pneumonie außerhalb der Intensivstation
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.<p>
Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study will be a pragmatic trial in which prospectively enrolled patients will be randomly assigned to Ceftriaxone dosed either 1 gram or 2 grams daily. When a clinician in the emergency department or non-intensive care inpatient ward orders Ceftriaxone and selects 'community-acquired pneumonia' as the indication, the electronic health record software used at the study sites (Epic) will prompt the ordering clinician to opt into the study. No direct patient contact will occur.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
- Name: Jonathan D Baghdadi, MD, PhD
- Telefonnummer: 410-706-0066
- E-Mail: jbaghdadi@som.umaryland.edu
Studienorte
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- University of Maryland Medical Center
-
Kontakt:
- Megan Dunning, MD
- Telefonnummer: 410-328-8667
- E-Mail: mdunning@ihv.umaryland.edu
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- University of Maryland Medical Center - Midtown Campus
-
Kontakt:
- Jonathan Baghdadi, MD, PhD
- Telefonnummer: 410-225-8000
- E-Mail: jbaghdadi@som.umaryland.edu
-
Glen Burnie, Maryland, Vereinigte Staaten, 21061
- UM Baltimore Washington Medical Center
-
Kontakt:
- Stephanie Pires, PharmD
- Telefonnummer: 410-787-4000
- E-Mail: Stephanie.Pires@umm.edu
-
Towson, Maryland, Vereinigte Staaten, 21204
- University of Maryland St. Joseph Medical Center
-
Kontakt:
- Rose Kohinke, PharmD
- Telefonnummer: 410-337-1000
- E-Mail: Rose.Kohinke@umm.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Evaluated in the emergency department or within 72 hours of hospitalization
- Prescribed Ceftriaxone for community-acquired pneumonia
Exclusion Criteria:
- Planned or present admission to an intensive care unit
- Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Low Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of non-critical community-acquired pneumonia. |
|
Aktiver Komparator: Moderate Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 2 grams daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed at 2 grams daily per institutional guidance for treatment of community-acquired pneumonia. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Antibiotic escalation within 5 days of randomization
Zeitfenster: The outcome will be assessed 5 days after enrollment
|
Defined by increasing the dose or frequency of Ceftriaxone, starting additional antibiotics not ordered concurrently with Ceftriaxone, or switching Ceftriaxone to an antibiotic with a broader spectrum up activity >24 hours after enrollment; antibiotic changes made on the calendar day of discharge in preparation for discharge alive from the hospital will not be considered escalation |
The outcome will be assessed 5 days after enrollment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to stability
Zeitfenster: The outcome will be assessed 90 days after enrollment
|
Time in days from randomization until stability defined by temperature < 38, heart rate < 100, respiratory rate < 24, oxygen saturation > 90%, systolic blood pressure ≥ 90, and return to baseline mental status based on Glasgow Coma Score over a 24-hour period |
The outcome will be assessed 90 days after enrollment
|
|
Clinical deterioration within 10 days of randomization
Zeitfenster: The outcome will be assessed 10 days after enrollment
|
Defined by admission to an intensive care unit, mechanical ventilation, or in-hospital mortality on any hospital day, or supplemental oxygen >5 L after hospital day 3 during the index encounter |
The outcome will be assessed 10 days after enrollment
|
|
Ceftriaxone-associated toxicity within 10 days of randomization
Zeitfenster: The outcome will be assessed 10 days after enrollment
|
Defined by new development of Hemoglobin < 10, elevated liver enzymes or or total bilirubin, clinically significant diarrhea (represented by Clostridioides difficile testing), or rash (represented by consult to dermatology) |
The outcome will be assessed 10 days after enrollment
|
|
Ranked composite outcome
Zeitfenster: The outcome will be assessed 30 days after enrollment
|
Rank 1 (highest rank) = no antibiotic escalation, clinical deterioration, or Ceftriaxone-associated toxicity Rank 2 = antibiotic escalation without clinical deterioration or Ceftriaxone-associated toxicity Rank 3 = Ceftriaxone-associated toxicity without clinical deterioration Rank 4 = clinical deterioration without 30-day mortality Rank 5 = 30-day mortality |
The outcome will be assessed 30 days after enrollment
|
|
Duration of antibiotics
Zeitfenster: The outcome will be assessed 90 days after enrollment
|
Defined as the total days of antibiotic therapy during the hospital encounter |
The outcome will be assessed 90 days after enrollment
|
|
Hospital length of stay
Zeitfenster: The outcome will be assessed 90 days after enrollment
|
Duration of hospitalization in days |
The outcome will be assessed 90 days after enrollment
|
|
All-cause readmission
Zeitfenster: The outcome will be assessed 90 days from enrollment
|
Readmission for any reason within 30 days of hospital discharge |
The outcome will be assessed 90 days from enrollment
|
|
In-hospital mortality
Zeitfenster: The outcome will be assessed 90 days after enrollment
|
In-hospital death or discharge to hospice |
The outcome will be assessed 90 days after enrollment
|
|
Clostridioides difficile infection
Zeitfenster: The outcome will be assessed 90 days after enrollment
|
Positive laboratory test for Clostridioides difficile within 30 days of randomization |
The outcome will be assessed 90 days after enrollment
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HP-00117776
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .